Merck is accelerating its European expansion plans for single-use products critical to manufacturing vaccines and lifesaving therapies.
The life science company is adding a single-use assembly production unit at its Life Science Center in Molsheim, France.
With the €25 million investment, the company is accelerating its European expansion plans for this key technology, which is used for the production of COVID-19 vaccines and other lifesaving therapies.
Molsheim will be the first site in Europe where Merck manufactures the product. Further production sites are located in Danvers, Massachusetts, USA, and Wuxi, China.
Belén Garijo, Vice Chair of the Executive Board and Deputy CEO of Merck, said: “The pandemic has confronted the world with inconceivable challenges. Merck’s science and technology efforts have resulted in significant contributions since the outset of COVID-19.
“Our new European production unit will increase capacity of the urgently needed supply of single-use assemblies to vaccine and therapeutic manufacturers worldwide.”
The investment in Molsheim will add more than 350 new jobs in total along with 1,700 square meters of ISO7 or ISO5 cleanrooms, using modular building design and existing infrastructure to allow future expansions without any disruptions.
The new unit will produce Mobius single-use assemblies, a key offering that is part of Merck’s Mobius® MyWay program. It is planned to be operational by the end of 2021.